<
 
 
 
 
>
hide
You are viewing a Web site, archived on 21:01:18 Oct 30, 2004. It is now a Federal record managed by the National Archives and Records Administration.
External links, forms, and search boxes may not function within this collection.
U.S. Food and Drug Administration
horizonal rule

Congressional Testimony

1998

 

October

  • Dr. Michael A. Friedman, October 7, 1998
    Acting Commissioner, Food and Drug Administration, before the Committee on Commerce to reconfirm the commitment of the Food and Drug Administration (FDA or the Agency) to full and timely implementation of the FDA Modernization Act of 1997 (FDAMA or the Act).
  • Sharon Smith-Holston, October 2, 1998
    Deputy Commissioner for External Affairs, Food and Drug Administration, before the Committee on Commerce on Sector Annex for Pharmaceutical Good Manufacturing Practices (the Annex) of the Agreement on Mutual Recognition between the United States of America and the European Community (MRA).

September

  • William B. Schultz, September 24, 1998
    Deputy Commissioner for Policy, Food and Drug Administration, before the Committee on Government Affairs on safety of imported foods.
  • John Callan, Ph.D., September 24, 1998
    Assistant Secretary for Management and Budget, and Chief Information Officer (CIO) for the Department of Health and Human Services (DHHS) before the Committee on Veterans' Affairs on information on the Year 2000 date issue as it relates to medical devices.
  • Dr. Michael A. Friedman, September 9, 1998
    Acting Commissioner of Food and Drug Administration, before the Committee on Government Reform and Oversight on FDA's regulatory compliance program which helps assure the safety of blood and plasma derivatives through the application of good manufacturing practices (GMP) as well as the continuing shortage of immune globulin, intravenous (Human) (IGIV), the subject of the subcommittee hearing on May 7 of this year.

July

  • Dr. Michael A. Friedman, July 23, 1998
    Acting Commissioner, Food and Drug Administration, before the Special Committee on the Year 2000 Technology Problem on the Year 2000 date issue as it relates to medical devices.
  • Dr. Bruce Burlington, July 23, 1998
    Director, Center for Devices and Radiological Health, Food and Drug Administration, before the Subcomittee on Health and the Environment on FDA's regulation of over-the-counter (OTC) test systems for drugs of abuse.

May

  • Dr. Bruce Burlington, May 8, 1998
    Director, Center for Devices and Radiological Health, Food and Drug Administration, before the Subcomittee on Health and the Environment on the critical importance of safeguarding womens health with Dr. Florence Houn, Director, of the Division of Mammography Quality and Radiation Programs at CDRH.
  • Michael A. Friedman, M.D., May 7, 1998
    Lead Deputy Commissioner of Food and Drug Administration, before the Committee on Government Reform and Oversight on the shortage of immune globulin products and the efforts of FDA to respond to the shortages.
  • John Jenkins, M.D., May 6, 1998
    Director, Division of Pulmonary Drug Products at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration, before the Committee on Labor and Human Resources on the implementation of Title VI of the Clean Air Act as it relates to the use of chlorofluorocarbons (CFCs) in metered-dose inhalers (MDIs).

April

  • Michael A. Friedman, M.D., April 30, 1998
    Lead Deputy Commissioner of Food and Drug Administration, before the Congressional Caucus for Women's Issues on our cancer initiative, and some of the Agency's activities related to women's health, such as women in clinical trials and our Take Time To Care initiative.
  • Michael A. Friedman, M.D., April 22, 1998
    Lead Deputy Commissioner of Food and Drug Administration, before the Committee on Government Reform and Oversight on various programs for providing access to promising therapies for seriously ill and dying patients.
  • John Jenkins, M.D., April 2, 1998
    Director of the Pulmonary Drug Products Division at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration, before the Committee on Labor and Human Resources on the implementation of Title VI of the Clean Air Act as it relates to the use of chlorofluorocarbons (CFCs) in metered-dose inhalers (MDIs).
  • Michael A. Friedman, M.D., April 1, 1998
    Lead Deputy Commissioner of Food and Drug Administration, (FDA or the Agency) management and procurement policies and practices in general, and specifically as they relate to CBER.

March

  • Randolph F. Wykoff, M.D, March17, 1998
    Associate Commissioner for Operations, Food and Drug Administration before the Committee on Veterans' Affairs to discuss the Agency's role in the medical, chemical, and biological warfare preparedness program of the Department of Defense (DOD).

February

  • William B. Schultz, February 10, 1998
    Deputy Commissioner for Policy, Food and Drug Administration, before the Committee on Labor and Human Resources on proposals for comprehensive tobacco legislation.

 

Testimony Archive

 

rule link to FDA home page link to U.S. Department of Health and Human Services FDA logo--link to FDA home page